PMDAapproval83% confidence
[SHINSA]List of Approved Drugs: April 2004 to February 2026
Source: PMDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable approval decision relevant to Merck.
Regulatory Analysis
PMDA regulatory document relevant to this signal.
Supporting Context
- Therapeutic area
- Infectious Disease · Respiratory Syncytial Virus (RSV)
- Sub-indication
- General
Related signal: Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants